| _version_ |
1860797485028474880
|
| building |
INTELEK Repository
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| date |
2016-04-27 10:54:56
|
| format |
Restricted Document
|
| id |
12923
|
| institution |
UniSZA
|
| internalnotes |
[1] Kim, NY; Pae, HO; Ko, YS; Yoo, JC; Choi, BM; Jun, CD; Chung, HT; Inagaki, M; Higuchi, R; Kim, YC, Planta Med.,1999, 65: 656-658. [2] Kim HC, An RB, Jeong GS, Oh SH, Kim YC. Nat. Prod. Sci, 2005,11: 150-154. [3] Eun-Ju Yang, Sang-In Kim, et al. Arch Pharm Res, 2010, 33(4):531-538. [4] Liu KY, Wu YC, et al., Neurosci Lett, 2008, 434(2):195-9. [5] Huang, Linzhang Zhao, et al.(2011) Die Pharmazie – Int J Pharm. Sci,66(2):83-97. [6] Choi J Shin KM, et al., Planta med, 2004, 70 (11):1027-32. [7] Marlene Rabinovitch, Christophe Guignabert, Marc Humbert, Mark R. Nicolls. Circulation Research 2014, 115: 165-175. [8] Carmen De Miguel, Nathan P. Rudemiller, Justine M. Abais, David L. Mattson. Current Hypertension Reports, 2015,17:507. [9] Wu Js, Hong Hs. Chin J Clin Pharmacol Ther, 2006, 2:136-140. [10] Bashir Ado Ahmad, Khamsah Suryati Mohd, Muhammad Abdurrazak, U. S Mahadeva Rao, thant zin. Int J Pharm Pharm Sci, 2015, Vol 7, Issue 5, 242-247. [11] Li L, Zheng C Fau - Fu Y, et al., Biol. Trace. Res, 2012, 145(1): 101-108. [12] Ribeiro Rde A, de Barros FF, et al., J. Ethnophrmacol, 1988, 24(1): 19-29. [13] Imam MZ, Akter, S. Journal of Applied Pharmaceutical Science. 2011. 01 (05):14-20. [14] Choi J, Shin KM, Park HJ, Jung HJ, Kim HJ, Lee YS, Rew JH, Lee KT. Planta Med. 2004. 70(11):1027-1032. [15] Agerskov,Maria Wallin,Per Hellström,Carsten Wikkelsö,Mats Tullberg. Fluids Barriers CNS 2015, 12 (Suppl 1): 011. [16] Alessandra Manes, Massimiliano Palazzini, Enri Leci, Maria L. Bacchi Reggiani, Angelo Branzi, Nazzareno Galiè. European Heart Journal, 2013, Volume 35, Issue 11Pp. 716 – 724. [17] Julie G. Sweet, Siu-Lung Chan, Marilyn J. Cipolla. Journal of Applied Physiology 2015, 119(7):817-823. [18] Philip Thomas, Indranil Dasgupta. Pediatric Nephrology 2015, 30(4):549-560. [19] Schiffrin, Ernesto L. Journal of Hypertension, 2014, 32(2):228–229. [20] Xin-Fang Leong, Chun-Yi Ng,Kamsiah Jaarin. BioMed Research International. 2015, Volume 2015, Article ID 528757, 11 pages. [21] Sun L,Gao Yh,Tian D K,Zheng Jp,Zhuc Y,Ke Y, et al. Acta Physiologica Sinaca 2006, 4:318-323. [22] Alexandra Groth, Bart Vrugt, Matthias Brock, Rudolf Speich, Silvia Ulrich, Lars C Huber. Respiratory Research, 2014, 15:47. [23] Sylvia Cohen-Kaminsky, Aurélie Hautefort1,Laura Price, Marc Humbert, Frédéric Perros. Drug Discovery Today, 2014, 19(8):1251–1256. [24] H. Oliveira-Paula, Gustavo, Lacchini, Riccardo, E. Tanus-Santos, Jose. Current Drug Targets, 2014, 15(2):164-174(11). [25] Li H,xiao CS,wang l,yang HY. Chinese Journal of Pathophysiology, 2011,4: 653-657. [26] Mansoor Ahmad, and Khalid Aftab. Phytotherapy Research. 1995, Volume 9, Issue 6, pages 452–454. [27] Sun L,Gao Yh,Tian D K,Zheng Jp,Zhuc Y, Key, et al. Acta Physiologica Sinaca, 2006, 4:318-323. [28] Jung CH, Jung H, Shin YC, Park JH, Jun CY, Kim HM, Yim HS, Shin MG, Bae HS, Kim SH, Ko SG. J. Ethnopharmacol, 2007, 113: 183-187. [29] Niu HS, Hsu FL, Liu IM, Neurosci. Lett., 2008a, 445: 113-116. [30] Niu HS, Liu IM, Cheng JT, Lin CL, Hsu FL. Planta Med., 2008b, 74: 109-113. [31] Peng T, Wang J, Zhen JH, Hu Z, Yang XD. Biomedical Reports, 2014, 277 : 490-494. [32] Ding H. Chin. J Clin Health, 2010, 4:372-373. [33] Yu X,Zhang Bh,Yu Ml,Liu Xy,Wang L,Yang Z. Chin, J Lab Diagn, 2011, 3:492-495.
|
| originalfilename |
7230-01-FH02-FP-16-05743.jpg
|
| person |
norman
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12923
|
| spelling |
12923 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12923 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal image/jpeg inches 96 96 norman 771 1416x771 1416 34 34 2016-04-27 10:54:56 7230-01-FH02-FP-16-05743.jpg UniSZA Private Access The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats Der Pharmacia Lettre To investigate the effect of syringin (SYN) on TNF-α, iNOS, ICAM-1 and its’ mRNA expression in the heart, brain and kidneys of spontaneously hypertensive rats (SHR), and reveal the mechanism of its anti-inflammatory injury in hypertension target organs. SHRs were randomly divided into 5 groups including the model group (Group-2), the high-dose (G-4), medium-dose (G-5), low-dose (G-6) SYN group and the benazepril group (G-3), with 5 rats in each group. Wistar Kyoto (WKY) rats were used for the normal control group (G-1). Non-invasive blood pressure (BP) instruments were used to measure systolic blood pressure in the rats tail artery; used western blot to analyze the expression of TNF-α, iNOS, ICAM-1 and used reverse transcription-polymerase chain reaction (RT-PCR) to analyze the expression of TNF-α, iNOS, ICAM-1 mRNA. Compared with the normal control group, the model group’s BP level was significantly increased (P0.05); compared with the normal control group, the expression of TNF-α, iNOS, ICAM-1 and its’ mRNA in the model group was significantly increased (P0.05). SYN had no significant BP lowering effect; SHR showed inflammatory injury in the heart, brain and kidneys; improvement on the inflammatory injury, and in turn, the anti-inflammation mechanism may be associated with lowering TNF-α, iNOS and ICAM-1 and its’ mRNA expression. 8 3 53-61 [1] Kim, NY; Pae, HO; Ko, YS; Yoo, JC; Choi, BM; Jun, CD; Chung, HT; Inagaki, M; Higuchi, R; Kim, YC, Planta Med.,1999, 65: 656-658. [2] Kim HC, An RB, Jeong GS, Oh SH, Kim YC. Nat. Prod. Sci, 2005,11: 150-154. [3] Eun-Ju Yang, Sang-In Kim, et al. Arch Pharm Res, 2010, 33(4):531-538. [4] Liu KY, Wu YC, et al., Neurosci Lett, 2008, 434(2):195-9. [5] Huang, Linzhang Zhao, et al.(2011) Die Pharmazie – Int J Pharm. Sci,66(2):83-97. [6] Choi J Shin KM, et al., Planta med, 2004, 70 (11):1027-32. [7] Marlene Rabinovitch, Christophe Guignabert, Marc Humbert, Mark R. Nicolls. Circulation Research 2014, 115: 165-175. [8] Carmen De Miguel, Nathan P. Rudemiller, Justine M. Abais, David L. Mattson. Current Hypertension Reports, 2015,17:507. [9] Wu Js, Hong Hs. Chin J Clin Pharmacol Ther, 2006, 2:136-140. [10] Bashir Ado Ahmad, Khamsah Suryati Mohd, Muhammad Abdurrazak, U. S Mahadeva Rao, thant zin. Int J Pharm Pharm Sci, 2015, Vol 7, Issue 5, 242-247. [11] Li L, Zheng C Fau - Fu Y, et al., Biol. Trace. Res, 2012, 145(1): 101-108. [12] Ribeiro Rde A, de Barros FF, et al., J. Ethnophrmacol, 1988, 24(1): 19-29. [13] Imam MZ, Akter, S. Journal of Applied Pharmaceutical Science. 2011. 01 (05):14-20. [14] Choi J, Shin KM, Park HJ, Jung HJ, Kim HJ, Lee YS, Rew JH, Lee KT. Planta Med. 2004. 70(11):1027-1032. [15] Agerskov,Maria Wallin,Per Hellström,Carsten Wikkelsö,Mats Tullberg. Fluids Barriers CNS 2015, 12 (Suppl 1): 011. [16] Alessandra Manes, Massimiliano Palazzini, Enri Leci, Maria L. Bacchi Reggiani, Angelo Branzi, Nazzareno Galiè. European Heart Journal, 2013, Volume 35, Issue 11Pp. 716 – 724. [17] Julie G. Sweet, Siu-Lung Chan, Marilyn J. Cipolla. Journal of Applied Physiology 2015, 119(7):817-823. [18] Philip Thomas, Indranil Dasgupta. Pediatric Nephrology 2015, 30(4):549-560. [19] Schiffrin, Ernesto L. Journal of Hypertension, 2014, 32(2):228–229. [20] Xin-Fang Leong, Chun-Yi Ng,Kamsiah Jaarin. BioMed Research International. 2015, Volume 2015, Article ID 528757, 11 pages. [21] Sun L,Gao Yh,Tian D K,Zheng Jp,Zhuc Y,Ke Y, et al. Acta Physiologica Sinaca 2006, 4:318-323. [22] Alexandra Groth, Bart Vrugt, Matthias Brock, Rudolf Speich, Silvia Ulrich, Lars C Huber. Respiratory Research, 2014, 15:47. [23] Sylvia Cohen-Kaminsky, Aurélie Hautefort1,Laura Price, Marc Humbert, Frédéric Perros. Drug Discovery Today, 2014, 19(8):1251–1256. [24] H. Oliveira-Paula, Gustavo, Lacchini, Riccardo, E. Tanus-Santos, Jose. Current Drug Targets, 2014, 15(2):164-174(11). [25] Li H,xiao CS,wang l,yang HY. Chinese Journal of Pathophysiology, 2011,4: 653-657. [26] Mansoor Ahmad, and Khalid Aftab. Phytotherapy Research. 1995, Volume 9, Issue 6, pages 452–454. [27] Sun L,Gao Yh,Tian D K,Zheng Jp,Zhuc Y, Key, et al. Acta Physiologica Sinaca, 2006, 4:318-323. [28] Jung CH, Jung H, Shin YC, Park JH, Jun CY, Kim HM, Yim HS, Shin MG, Bae HS, Kim SH, Ko SG. J. Ethnopharmacol, 2007, 113: 183-187. [29] Niu HS, Hsu FL, Liu IM, Neurosci. Lett., 2008a, 445: 113-116. [30] Niu HS, Liu IM, Cheng JT, Lin CL, Hsu FL. Planta Med., 2008b, 74: 109-113. [31] Peng T, Wang J, Zhen JH, Hu Z, Yang XD. Biomedical Reports, 2014, 277 : 490-494. [32] Ding H. Chin. J Clin Health, 2010, 4:372-373. [33] Yu X,Zhang Bh,Yu Ml,Liu Xy,Wang L,Yang Z. Chin, J Lab Diagn, 2011, 3:492-495.
|
| spellingShingle |
The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats
|
| summary |
To investigate the effect of syringin (SYN) on TNF-α, iNOS, ICAM-1 and its’ mRNA expression in the heart, brain and kidneys of spontaneously hypertensive rats (SHR), and reveal the mechanism of its anti-inflammatory injury in hypertension target organs. SHRs were randomly divided into 5 groups including the model group (Group-2), the high-dose (G-4), medium-dose (G-5), low-dose (G-6) SYN group and the benazepril group (G-3), with 5 rats in each group. Wistar Kyoto (WKY) rats were used for the normal control group (G-1). Non-invasive blood pressure (BP) instruments were used to measure systolic blood pressure in the rats tail artery; used western blot to analyze the expression of TNF-α, iNOS, ICAM-1 and used reverse transcription-polymerase chain reaction (RT-PCR) to analyze the expression of TNF-α, iNOS, ICAM-1 mRNA. Compared with the normal control group, the model group’s BP level was significantly increased (P0.05); compared with the normal control group, the expression of TNF-α, iNOS, ICAM-1 and its’ mRNA in the model group was significantly increased (P0.05). SYN had no significant BP lowering effect; SHR showed inflammatory injury in the heart, brain and kidneys; improvement on the inflammatory injury, and in turn, the anti-inflammation mechanism may be associated with lowering TNF-α, iNOS and ICAM-1 and its’ mRNA expression.
|
| title |
The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats
|
| title_full |
The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats
|
| title_fullStr |
The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats
|
| title_full_unstemmed |
The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats
|
| title_short |
The effect of syringin on the expression of TNF-α, iNOS, ICAM-1 and its' mRNA in the heart, brain and kidneys of spontaneously hypertensive rats
|
| title_sort |
effect of syringin on the expression of tnf-α, inos, icam-1 and its' mrna in the heart, brain and kidneys of spontaneously hypertensive rats
|